Advertisement
UK markets open in 5 hours 53 minutes
  • NIKKEI 225

    37,736.54
    -225.26 (-0.59%)
     
  • HANG SENG

    16,251.84
    +2.87 (+0.02%)
     
  • CRUDE OIL

    82.69
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,384.10
    -4.30 (-0.18%)
     
  • DOW

    37,753.31
    -45.66 (-0.12%)
     
  • Bitcoin GBP

    49,415.98
    -1,989.75 (-3.87%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,683.37
    -181.88 (-1.15%)
     
  • UK FTSE All Share

    4,273.02
    +12.61 (+0.30%)
     

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

High demand for coronavirus vaccines earlier in the pandemic pushed Moderna's (NASDAQ: MRNA) earnings into the stratosphere. In fact, Moderna could continue to generate billions in revenues annually from its first -- and so far, only -- approved product. For example, Moderna sold its vaccine to the U.S. government for about $26 a dose.